Tradestie Institutional Equity Comparison Engine

INCY vs ARIA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

INCY Overall Edge

INCY Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Incyte Genomics Inc (INCY) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, INCY trades at 13.9x Forward P/E with 32.2% operating margin (+14.0% YoY revenue) versus ARIA at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, INCY sits in CONSOLIDATION (73rd %ile IV; Dealer Gamma Walls on Pro) against ARIA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner INCY
INCY 13.9x vs ARIA N/M Fwd P/E
Growth & Margin Winner INCY
Op Margin 32.2% vs N/A ยท YoY +14.0% vs N/A
Momentum & Technical Winner INCY
1Y +14.1% vs -17.0% ยท 52W Pos 72% vs 0%
Options & Structure Winner INCY
CONSOLIDATION (73rd %ile IV) vs UNCLASSIFIED (N/A IV)
INCY NASDAQ
Incyte Genomics Inc
Services-Commercial Physical & Biological Research
$120.27
-0.58% 1D
Market Cap $24.7B
1M Return +6.37%
1Y Return +14.1%
Forward P/E 13.9x
Unified AI Score
58.9 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 68.0 Mom 60.0
ARIA US Equity
ARIA
Institutional Equity
$21.03
-3.52% 1D
Market Cap N/A
1M Return -11.55%
1Y Return -16.97%
Forward P/E N/M
Unified AI Score
47.7 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: INCY +14.1% ARIA -16.97% Spread: +15.92 pp (INCY Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
INCY TTM Op. Margin: 32.2% ARIA TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on INCY vs ARIA. Trailing 12-month operating profitability (INCY 32.2% vs ARIA N/A) and valuation multiples (INCY 13.9x vs ARIA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: INCY (10) vs ARIA (0)
Institutional Metric INCY ARIA Criterion Row Winner
Market Capitalization Scale $24.7B N/A Larger Scale INCY
Trailing P/E Ratio Valuation 61.7x N/M Lower Multiple INCY
Forward P/E Ratio Valuation 13.9x N/M Lower Multiple INCY
Revenue Growth (YoY) Growth +14.0% N/A Higher Growth INCY
Operating Margin (TTM) Profitability 32.2% N/A Higher Margin INCY
Net Profit Margin Profitability 6.7% N/A Higher Margin INCY
Return on Equity (ROE) Capital Efficiency 7.8% N/A Higher ROE INCY
52-Week Range Position Momentum 72% ($89โ€“$133) 0% ($21โ€“$27) Stronger Trend INCY
Beta / 30D Volatility Risk Regime 0.30ฮฒ ยท 35% Vol 1.92ฮฒ ยท 43% Vol Lower Realized Risk INCY
Unified Institutional Score Composite Signal 58.9 / 100 (HOLD) 47.7 / 100 (HOLD) Higher Composite INCY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full INCY vs ARIA Buy Guide
INCY CONSOLIDATION
78d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 73rd %ile
IV Regime Elevated (60thโ€“80th %ile)
Live INCY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ARIA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ARIA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither INCY nor ARIA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.